Bupropion SR Dosing for Smoking Cessation in a 70-Year-Old Male with COPD
For this 70-year-old male with COPD seeking smoking cessation, start bupropion SR at 150 mg once daily for 3 days, then increase to 150 mg twice daily (maximum 300 mg/day) for 7-12 weeks, beginning 1-2 weeks before the quit date. 1
Standard Dosing Regimen
The NCCN guidelines provide clear dosing instructions 1:
- Days 1-3: 150 mg orally once daily (morning)
- Day 4 through 12 weeks: 150 mg orally twice daily (if tolerated)
- Maximum daily dose: 300 mg per day
- Timing: Initiate 1-2 weeks prior to the target quit date
- Duration: 7-12 weeks (may extend to 6 months-1 year to promote continued cessation)
Critical timing consideration: Space doses at least 6 hours apart to minimize seizure risk 2. Avoid bedtime doses to reduce insomnia 2.
Evidence Supporting Use in COPD
Bupropion SR is specifically effective and well-tolerated in patients with COPD. A landmark randomized controlled trial in 404 COPD patients demonstrated continuous abstinence rates of 28% (weeks 4-7) with bupropion SR versus 16% with placebo (p=0.003), with maintained superiority at 6 months (16% vs 9%, p<0.05) 3. A subsequent trial confirmed efficacy in COPD patients with an 18.9% absolute difference versus placebo in prolonged abstinence 4.
Special Considerations for This Patient
Age-Related Factors
While the FDA label does not mandate specific dose adjustments for age alone 2, consider:
- Start low, go slow: The initial 3-day titration at 150 mg daily is particularly important in older adults
- Monitor closely for side effects during dose escalation
COPD-Specific Considerations
COPD is NOT a contraindication to bupropion SR. In fact, evidence specifically supports its use in this population 3, 4. The medication attenuates tobacco craving and withdrawal symptoms effectively in COPD patients 3.
Contraindications to Screen For
Absolute contraindications 1, 2:
- Seizure disorder or history of seizures
- Current or prior eating disorder (bulimia/anorexia)
- Abrupt discontinuation of alcohol or benzodiazepines
- Concurrent MAO inhibitor use (or within 14 days)
- Severe hepatic cirrhosis
- Closed-angle glaucoma
- Concurrent tamoxifen use
If severe hepatic cirrhosis is present: Maximum dose is 75 mg once daily 2
If renal impairment is present: Use with caution; consider reduced frequency/dose 2
Common Side Effects and Management
The most common side effects are dry mouth and insomnia 1, 5:
- Insomnia occurs frequently but is usually mild and can be managed by avoiding bedtime doses 2
- Dry mouth is dose-related and typically transient 6
- Most adverse effects occur within the first 30 days 7
Seizure risk: Approximately 1 in 1,000 at recommended doses 5, 8. This risk is minimized by:
- Not exceeding 150 mg per single dose
- Spacing doses at least 6 hours apart
- Screening for predisposing factors
Neuropsychiatric Monitoring
Monitor for neuropsychiatric symptoms (depression, suicidal ideation, agitation, hostility), though recent evidence shows these are not significantly increased versus placebo 1. The FDA removed the black box warning for neuropsychiatric events based on the EAGLES trial, which found no significant increase in neuropsychiatric adverse events with bupropion versus nicotine patches or placebo 1.
Combination Therapy Option
If monotherapy fails, consider adding nicotine replacement therapy (NRT) to bupropion SR 1. The combination is safe and may improve outcomes, though bupropion alone is effective in COPD 3.
Practical Implementation
- Screen for contraindications (especially seizure history, eating disorders, alcohol/benzodiazepine use)
- Assess hepatic and renal function if clinically indicated
- Set a quit date 1-2 weeks after starting medication
- Provide behavioral counseling alongside pharmacotherapy 1
- Monitor for side effects at follow-up visits, especially in first month
- Minimize alcohol consumption during treatment 2
- Discontinue immediately if seizure occurs 2
Duration and Discontinuation
Continue for 7-12 weeks minimum 1. Therapy may be extended to 6 months-1 year to maintain cessation, though longer periods should be avoided if possible 1. If no clinical improvement after appropriate treatment period, consider switching to varenicline or combination NRT 1.